News
Abbott Laboratories, The Q2
Digest more
Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...
Abbott did not factor in the decision during Sunday's loss to the Mets. He allowed two runs on six hits and a walk over six innings while striking out five.
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...
Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...
Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...
Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.
Explore more
Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...
Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...
The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.
Just a day after the S&P 500 and Nasdaq climbed into record territory, U.S. stocks end mixed, with American Express (AXP) and 3M (MMM) dragging the Dow, and more tariff drama muting markets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results